###begin article-title 0
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 97 100 97 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
Depending on the population studied, large genomic rearrangements (LGRs) of the mismatch repair (MMR) genes constitute various proportions of the germline mutations that predispose to hereditary non-polyposis colorectal cancer (HNPCC). It has been reported that loss of heterozygosity (LOH) at the LGR region occurs through a gene conversion mechanism in tumors from MLH1/MSH2 deletion carriers; however, the converted tracts were delineated only by extragenic microsatellite markers. We sought to determine the frequency of LGRs in Slovak HNPCC patients and to study LOH in tumors from LGR carriers at the LGR region, as well as at other heterozygous markers within the gene to more precisely define conversion tracts.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS2</italic>
###xml 201 211 201 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1/MSH2 </italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
The main MMR genes responsible for HNPCC, MLH1, MSH2, MSH6, and PMS2, were analyzed by MLPA (multiplex ligation-dependent probe amplification) in a total of 37 unrelated HNPCC-suspected patients whose MLH1/MSH2 genes gave negative results in previous sequencing experiments. An LOH study was performed on six tumors from LGR carriers by combining MLPA to assess LOH at LGR regions and sequencing to examine LOH at 28 SNP markers from the MLH1 and MSH2 genes.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
We found six rearrangements in the MSH2 gene (five deletions and dup5-6), and one aberration in the MLH1 gene (del5-6). The MSH2 deletions were of three types (del1, del1-3, del1-7). We detected LOH at the LGR region in the single MLH1 case, which was determined in a previous study to be LOH-negative in the intragenic D3S1611 marker. Three tumors displayed LOH of at least one SNP marker, including two cases that were LOH-negative at the LGR region.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
LGRs accounted for 25% of germline MMR mutations identified in 28 Slovakian HNPCC families. A high frequency of LGRs among the MSH2 mutations provides a rationale for a MLPA screening of the Slovakian HNPCC families prior scanning by DNA sequencing. LOH at part of the informative loci confined to the MLH1 or MSH2 gene (heterozygous LGR region, SNP, or microsatellite) is a novel finding and can be regarded as a partial LOH. The conversion begins within the gene, and the details of conversion tracts are discussed for each case.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 464 467 464 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR</italic>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 740 741 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
###xml 951 959 <span type="species:ncbi:9606">patients</span>
Hereditary non-polyposis colorectal cancer, HNPCC (also known as Lynch syndrome), is a frequent, autosomal, dominantly-inherited predisposition mainly for early-onset of colorectal and endometrial cancers, and less frequently for other type of malignancies [1]. The clinical definition of HNPCC diagnosis is based largely on the Amsterdam criteria (AC), which were set up in 1991 with the purpose of selecting families for mutational screening of mismatch repair (MMR) genes, whose germline pathogenic mutations cause this condition [2,3]. The less stringent Bethesda guidelines (BG), and later, the Revised Bethesda Guidelines (RBG) were established to identify additional HNPCC patients that do not fulfill the strict Amsterdam criteria [4]. The examination of tumor tissue of HNPCC-suspected patients for the presence of microsatellite instability (MSI) and/or alterations in the MMR protein expression patterns may be also useful in pre-selecting patients for mutational screening. Nevertheless, a precise distinction between familial and sporadic MMR deficient tumors before mutational screening still remains a complex issue [5] and not all of the clinico-genetical or tumor characteristics may be available for each case.
###end p 10
###begin p 11
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 330 352 330 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6, PMS2, PMS1, MLH3</italic>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
Identification of the predisposing germline mutation is important because it confirms the clinical diagnosis of HNPCC and enables targeted clinical surveillance, which significantly reduces cancer morbidity and mortality in Lynch syndrome families [6]. Taking into account the number of potentially mutated MMR genes (MLH1, MSH2, MSH6, PMS2, PMS1, MLH3) and different types of mutations, the screening approaches are very complex and involve many techniques. Despite the tremendous advances in molecular diagnosis of HNPCC that have been made since the discovery of genetic clues of this disease, the genetic etiology of many clinically defined HNPCC patients remains unsolved because of technical limitations and/or difficulties in confirming the pathogenicity of identified gene alterations [7].
###end p 11
###begin p 12
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 627 632 627 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 952 953 952 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1355 1359 1355 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1512 1514 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
###xml 1621 1629 <span type="species:ncbi:9606">patients</span>
Inherited large genomic rearrangements (LGRs) in the MMR genes, which are not detectable by commonly applied DNA sequencing, became a subject of numerous HNPCC studies in recent years. One of the goals of these studies was to determine the frequency of these mutations in HNPCC patients. Although direct comparisons of frequencies determined in the different studies are not possible due to variability in the way the cohorts were selected, it seems that in some populations, LGRs are more frequent than in others. LGRs are reported to comprise 10% to 55% of all MMR gene mutations, and most occur in major MMR genes; i.e. the MLH1 and MSH2 genes [8-17]. An exceptionally low frequency of LGRs in these two genes (<1.5%) was reported in a study of the Spanish population [18], though a higher frequency of LGRs was found in a Basque Country population [19]. The frequency of LGRs may be remarkably higher in certain populations due to founder effects [9,10,19-24]. There is no consensus on how to select patients for LGR-screening. In many studies, the patients who were previously screened by conventional screening/scanning methods (DGGE, HDA, DHPLC, DNA sequencing), and in whom no germline mutation could be found, are analyzed for the presence of LGR [25]. However, the examination of LGR prior to the laborious exon-by exon mutation scanning of the MMR genes has also been suggested and is feasible by applying simple and robust techniques, such as MLPA (multiplex ligation-probe dependent amplification) [18]. Knowing the frequency of LGR in the population can significantly influence the screening algorithms for patients at risk for HNPCC.
###end p 12
###begin p 13
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 367 377 367 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1/MSH2 </italic>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 943 948 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1331 1335 1331 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1341 1343 1341 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1344 1346 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1465 1467 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1671 1675 1671 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1724 1728 1724 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
Contrary to the germline LGRs, somatic LGRs in the MMR genes, which represent potential MMR inactivating events referred to as second hits during tumorigenesis, are rarely studied. The heterozygous LGR region present in the germline DNA can be used as a marker to study loss of heterozygosity (LOH) in the corresponding tumor DNA. One study showed that tumors of the MLH1/MSH2 germline LGR carriers often display a somatic mutation identical to one that is present in the germline DNA [1]. Furthermore, LOH analyses of these tumors using microsatellite markers flanking the respective gene have revealed that loss of the wild-type allele predominantly occurs through gene conversion, rather than mitotic recombination or physical deletion of the respective gene locus. Although in general, little is known about gene-conversion events that occur in cancer [26], it is likely that the conversion tracts do not encompass a whole sequence of the MLH1 or MSH2 gene in the LOH-positive cases. These two genes carry a number of single nucleotide polymorphisms (SNPs) that can be potentially utilized to delineate the conversion tracts more precisely than is possible using the extragenic microsatellite markers. The SNP markers, though less heterozygous than the microsatellite markers, have been proven to be useful in detecting LOH at MMR loci [27,28]. In their recent LOH study on the heterogeneously defined microsatellite unstable carcinomas, van Puijenbroek et al [29] used SNP arrays to assess LOH on a genome-wide level. Although, such commercial arrays are very attractive for LOH studies, they probably would not involve sufficient numbers of SNPs located within the MMR genes to enable a very detailed LOH study in the MMR gene of the LGR carriers.
###end p 13
###begin p 14
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 604 608 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
To date, among 58 clinically well-defined Slovak HNPCC families, 21 clearly pathogenic MMR gene mutations have been identified by applying direct DNA genomic sequencing [30,31]. As DNA sequencing fails to detect LGRs, it is possible that in some of these patients, an LGR is responsible for HNPCC. In the presented study, we used the MLPA technique to screen for LGRs in the MMR genes for the first time in the Slovak population. As a second step, we studied potential LOH events in those patients in whom the LGR was detected in the germline, by combining MLPA and DNA sequencing at the intragenic MLH1/MSH2-SNP markers.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 16
###begin p 17
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 804 812 <span type="species:ncbi:9606">patients</span>
###xml 1219 1227 <span type="species:ncbi:9606">patients</span>
###xml 1360 1368 <span type="species:ncbi:9606">patients</span>
This study included a total of 37 Slovak CRC patients investigated for the presence of LGR in the MMR genes. Eleven of these patients were enrolled in our previous study [32] while remaining 26 cases from cohort represented new patients referred to National Cancer Institute for genetic counselling after 2005. In summary, the patients were corresponding to: (a) 17 index cases of unrelated families that satisfied Amsterdam criteria I or II for HNPCC; (b) 20 unrelated index cases that satisfied Bethesda guidelines or Revised Bethesda Guidelines. The tumor specimens of 20 patients were tested for MSI (10 previously and other 10 in this study) and 18 could be analyzed for MMR protein expression by IHC (6 before and 12 now). In summary, at least one of these assays has been performed for each of 23 patients. MSI analyses in the current study were performed using new MSI Analysis System, Version 1.1 (Promega Co, Madison, WI), and the expression pattern of four MMR proteins (MLH1, MSH2, MSH6, and PMS2) was analyzed by standard IHC techniques as previously [33]. Because no pathogenic germline mutations could be detected by conventional mutation detection techniques (DGGE and/or sequencing) in the cohort, the patients were investigated for the presence of LGRs in their germline by MLPA (next section). Written informed consent was obtained from all patients included in this study. The study has been approved by The Ethics Committee of National Cancer Institute in Bratislava, and has been performed in accordance with the Declaration of Helsinki.
###end p 17
###begin title 18
LGR-screening and MLPA-based LOH analyses
###end title 18
###begin p 19
###xml 424 426 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 473 483 464 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1/MSH2 </italic>
###xml 1134 1135 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1136 1138 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1139 1141 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
DNA was isolated by either Qiagen QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany) or Recover Alltrade mark Total Nucleic Acid Isolation Kit (Applied Biosystems, Foster City, CA), depending on the source of material. For detection of aberrant exon(s) copy numbers in constitutional DNA, we used the SALSA MLPA kits MSH2/MLH1 (P003, version sold until 2006) and PMS2/MSH6 (P008) (MRC Holland, Amsterdam, The Netherlands) [34]. For MLPA-based LOH analyses in tumor DNA of MLH1/MSH2 LGR carriers, we used the P003 kit. After PCR amplification with 6-FAM-labeled primers, the samples were analyzed with an ABI 310 sequencer using GeneMapper software v 3.7 (Applied Biosystems, Inc., Foster City, CA). Specific peaks corresponding to each exon were identified according to their migration relative to the size standards and analyzed by MLPA-Excel spreadsheets for copy number changes. Dosage quotients equal to 0.5 (SD </= 20%) were considered deleted and dosage quotients 1.5 (SD </= 20%) duplicated. MLPA assay has been used for LOH detection by utilizing a heterozygous LGR region as a marker for LOH, similarly as described before [1,34,35], however LOH was calculated by using a formula: exon dosage quotient in the tumor DNA/exon dosage quotient in the germline DNA, that was applied on the exons affected in the germline. A value </= 0.5 indicated LOH at the site of large deletion and a value >/= 1.5 would indicate an LOH of the region duplicated in the germline. The identified exon(s) copy number changes were confirmed in at least two independent MLPA reactions.
###end p 19
###begin title 20
SNP-based LOH analyses using DNA sequencing
###end title 20
###begin p 21
###xml 25 26 25 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
The SNPs listed in Table 1 (n = 28) were analyzed by fluorescent capillary DNA sequencing. More SNPs (n = 18) were assessed for the MSH2 gene than for the MLH1 gene (n = 10), in order to cover large intronic regions in the central part (introns 6-8), as well as distal regions of the MSH2 gene. The sequences of the PCR primers used for the amplification of the regions containing SNP markers are provided in Table 2. The SNPs were visualized on an ABI PRISM 310 Genetic Analyzer. DNA sequencing at heterozygous SNP markers has been utilized for the evaluation of LOH, similarly as described previously [36,37], however for LOH assessment we used similar formula generally accepted for LOH determination by the microsatellite markers:
###end p 21
###begin p 22
SNP-based LOH markers used in this study.
###end p 22
###begin p 23
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>a </italic></sup>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>b</italic></sup>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 53 58 <span type="species:ncbi:9606">Human</span>
a SNP nomenclature reflecting the recommendations of Human Genome Variation Society; bAccording to the dbSNP at . For the determination of SNP location, the cDNA sequence alignements have been performed using NCBI RefSeq NM_000249.2 with genomic contigs NT_005580.6 and NT_022517.17 for the MLH1, and NM_000251.2 with genomic contig NT_022184.14 for the MSH2 gene.
###end p 23
###begin p 24
Primers for amplification of the fragments containing SNP markers.
###end p 24
###begin p 25
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </sup>
a size of amplicon in base pairs (bp); Note: several SNPs are located on the same amplicon
###end p 25
###begin p 26
The alleles with higher intensity of signal were set for N1 (in normal DNA) or T1 (in tumor DNA) while the alleles with lower intensity of signal were set for N2 (in normal DNA) or T2 (in tumor DNA), and ratios </= 0.5 implied the presence of LOH at the respective SNP marker.
###end p 26
###begin title 27
The definition of partial LOH
###end title 27
###begin p 28
The concurrent retention of heterozygosity of at least one marker and loss of heterozygosity of at least one other marker within the gene.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Screening of the LGRs in the germline DNA
###end title 30
###begin p 31
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 869 870 869 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 1134 1135 1134 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 1698 1702 1698 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1770 1775 1770 1775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1779 1783 1779 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS2</italic>
###xml 1803 1807 1803 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 1809 1814 1809 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH3 </italic>
###xml 1818 1822 1818 1822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH3</italic>
###xml 1942 1943 1942 1943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 1975 1980 1975 1980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 2056 2061 2056 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 2675 2677 2675 2677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 947 955 <span type="species:ncbi:9606">patients</span>
###xml 1495 1503 <span type="species:ncbi:9606">patients</span>
###xml 1993 2000 <span type="species:ncbi:9606">patient</span>
###xml 2176 2184 <span type="species:ncbi:9606">patients</span>
###xml 2309 2317 <span type="species:ncbi:9606">patients</span>
###xml 2891 2898 <span type="species:ncbi:9606">patient</span>
###xml 3210 3218 <span type="species:ncbi:9606">patients</span>
The cohort of 37 index patients at risk for HNPCC screened in this study for LGRs has been established mainly on the basis of clinico-genetical criteria for HNPCC (AC-I and II, BG and RBG) and a lack of a germline mutation in the major MMR genes (MLH1 and MSH2) by conventional mutation screening techniques. Eleven of these patients were extensively described in our previous study; the tumor specimens of 10 of them were analyzed by MSI assay in which 8 and 2 showed MSI-H and MSI-L status, respectively [32]. In the same study, 6 tumors were analyzed by IHC in which 2 analyses failed due to fixation problem and from 4 successfully stained tumors, 3 had a loss of MSH2 expression while one was MLH1 negative [32]. From 26 new cases, the tumor specimens of 10 of them were analyzed by MSI assay in which 9 and one showed MSI-H and MSI-L status, respectively. Figure 1 shows the representative pictures from these analyses. We have not included patients with stable tumors (MSS) in the study, however the MSI status for 17 cases from our cohort could not be analyzed because of no availability of fresh or FFPE tumor tissue. Figure 2 shows the representative pictures from IHC analyses. Twelve tumors were stained; 1 analysis failed due to fixation problem and from remaining 11 successfully stained tumors, 3 showed loss of MSH2 expression while eight were MLH1 negative. Because no pathogenic germline mutations could be detected by conventional mutation detection techniques in cohort, the patients were subjected to LGR screening by MLPA. In total, 7 LGRs were identified, all of which were detected using the SALSA MLPA kit P003 MSH2/MLH1. No deletions or duplications at the exons of other MMR genes detectable by SALSA MLPA kit P008 were observed (all exons of MSH6 and PMS2, and some exons of MLH1, MLH3 and MSH3). The clinico-pathological features of the LGR carriers and descriptions of identified changes are summarized in Table 3. Only one LGR was found in the MLH1 gene (in the patient SK-22)- a deletion of exons 5 and 6. LGRs found in the MSH2 gene represented a single duplication of exons 5 and 6 (SK-20 case) and three different types of deletions in five patients: an exon 1 deletion (SK-23), a deletion of exons 1-3 (SK-21 and SK-28), and a deletion of exons 1-7 (SK-14 and SK-25). Most patients with detected LGRs (5/7) fulfilled strict Amsterdam criteria for HNPCC. The two remaining LGR carriers complied with the less stringent Bethesda Guidelines. The average age of the LGR carriers at diagnosis was 38 years and three of them suffered from synchronous cancers. The MSI status of the tumors of five LGR carriers was known from our previous study [32]. These were SK-14, SK-20, SK-21, SK-22 with MSI-H tumors, and SK-23 who had low-level MSI cancer. The tumor tissue of the SK-25 case was not available for MSI analysis, however MSI-H status in the tumor of SK-28 patient was determined in recent study. The absence of MSH2 protein in tumors of the SK-20 and SK-21 cases, and a loss of the MLH1 protein expression in the SK-22 tumor detected by the IHC evaluation of tumor sections previously was in agreement with MLPA findings in this study. The mutations identified in five index patients were also present in 7 out of 10 tested relatives.
###end p 31
###begin p 32
Germline LGRs identified in Slovakian HNPCC families.
###end p 32
###begin p 33
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1 </italic>
###xml 363 366 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.a</italic>
###xml 428 436 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1 </italic>
###xml 444 447 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.d</italic>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 618 619 618 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 160 165 <span type="species:ncbi:9606">Human</span>
Fulfillment of HNPCC criteria: AC-I, AC-II, Amsterdam criteria I, II; BG, Bethesda guidelines. Systematic nomenclature: According to the recommendations of the Human Genome Variant Society using reference sequences NM_000249.2 (MLH1) and NM_000251.1 (MSH2). 5' deletion: the probes detecting regions located 15 or 27 kb before MSH2 localized in the TACSTD1 gene; n.a., not applicable; - no reduction of the signal at any of the TACSTD1 probes, n.d., not determined; MSI, microsatellite instability analysis: MSI-H, high level of MSI; MSI-L, low level of MSI; IHC, immunohistochemical analysis, +, a positive staining, -, a negative staining, * staining failed due to fixation problem; #, no FFPE tissue available for analysis; LOH, loss of heterozygosity, n.i. not informative in any LOH marker
###end p 33
###begin p 34
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSI analysis</bold>
###xml 14 15 14 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 29 30 29 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
MSI analysis. A: Normal DNA. B: Matching tumor DNA with MSI-H status. The presence of new alleles in the tumor sample (arrows) that were not present in the normal sample indicates microsatellite instability. The distribution of MSI markers and stable pentanucleotide markers is indicated in upper part of panel A.
###end p 34
###begin p 35
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IHC analyses</bold>
###xml 14 15 14 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 126 127 126 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
IHC analyses. A: An example of tumor with positive staining for MLH1. B: Same tumor as in A, with negative staining for MSH2. C: An example of tumor with negative staining for MLH1. D: Same tumor as in C, with positive staining for MLH1.
###end p 35
###begin title 36
Further characterization of identified LGRs
###end title 36
###begin p 37
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 805 806 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 917 925 917 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1 </italic>
###xml 950 954 950 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
In the MLPA assay, mutations and/or polymorphisms that are very close to the probe ligation site may also result in a reduced relative peak area. Therefore, deletions detected by a single probe (single exon deletions) always require confirmation. In order to confirm MSH2 deletion of exon 1 in the SK-23 case, we used the SALSA MLPA kit P008 PMS2/MSH6 including a single probe to MSH2 exon 1, different from the exon 1 probe present in the SALSA MLPA kit MSH2/MLH1 (P003). We again observed a reduction of peak area at exon 1 in the SK-23 case using the second kit, thus confirming the presence of this single exon deletion. The remaining four cases carrying multi-exonic MSH2 deletions involving exon 1 also displayed a reduction of peak area at the probe for MSH2 exon 1. In addition (as shown in Table 3), three patients exhibited an aberrant hybridization signal for one or two probes, which were confined to the TACSTD1 gene located upstream of MSH2.
###end p 37
###begin title 38
LOH analyses in tumors from LGR carriers
###end title 38
###begin p 39
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 186 191 186 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B, C</xref>
###xml 292 297 292 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3D, E</xref>
###xml 302 307 302 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3F, G</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 952 957 952 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 960 965 960 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1014 1015 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1170 1175 1170 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4E</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4F</xref>
###xml 1459 1463 1459 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4A-D</xref>
###xml 1531 1536 1531 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1938 1942 1938 1942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 2095 2097 2095 2097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 2837 2838 2837 2838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 2843 2844 2843 2844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
###xml 1489 1496 <span type="species:ncbi:9606">patient</span>
###xml 1779 1786 <span type="species:ncbi:9606">patient</span>
###xml 2253 2260 <span type="species:ncbi:9606">patient</span>
###xml 2441 2448 <span type="species:ncbi:9606">patient</span>
Six tumors from different LGR carriers were available for LOH analyses. MLPA revealed a somatic copy deletion identical to the germline deletion (MLH1 del5-6) in the SK-22 tumor (Figure 3B, C). Other tumors did not exhibit LOH at the heterozygous LGR region (two examples are shown on Figure 3D, E and 3F, G). Interestingly, as in the case of LOH at the LGR (SK-22), in the previous studies from our laboratory we have seen a retention of heterozygosity at intragenic microsatellite marker D3S1611 located in MLH1 intron 12 [32,38] [see additional file 1]. The case of retention of heterozygosity at one informative marker with a loss of heterozygosity at another informative marker within the same gene was subsequently termed 'partial LOH'. The observation of partial LOH in the MLH1 gene in the SK-22 tumor led us to search for SNP markers that are heterozygous/informative in our samples and enable a detailed examination of LOH within the mutated MLH1 or MSH2 gene. By testing the SNP markers listed in Table 1, we detected additional LOH events in three tumors. Germline DNA of the SK-22 case was heterozygous at the c.1-93G>A locus located in the promoter of the MLH1 gene and displayed LOH at this SNP (Figure 4E and 4F), indicating that the conversion covered not only the LGR region but also the region upstream of the LGR. The remaining two cases, neither of which showed LOH at the LGR region, exhibited LOH at the informative SNP markers (Figure 4A-D). The tumor of the SK-14 patient, which retained heterozygosity at MSH2 del1-7, displayed LOH at four SNPs (c.1511-91G>T and c.1511-9A>T in intron 9, c.1661+12G>A in intron 10, and c.1759+107A>G in intron 11), indicating the presence of a partial LOH located downstream of the LGR region. Germline DNA of the SK-20 patient was heterozygous at the c.1277-118G>A locus in intron 7 and showed LOH at this SNP. We had previously detected LOH by SNaPshot in the same case at two MSH2-SNPs located in intron 1 (c.211+9C>G, c.211+98T>C), which are difficult to sequence due to formation of secondary structures in the respective regions [28]. Taken together, two distinct LOH events interrupted by heterozygous dup5-6 (tandem arrangement assumed) are apparently present in the tumor of the SK-20 patient. In two cases (SK-21 and SK-23), no LOH was detected at any informative SNP, and the SK-28 germline DNA was SNP-uninformative. It has to be noted that for LOH measurements of each patient sample pair of normal and tumor tissue, the same tumor DNA isolation samples were analyzed in different assays taking in account of tumor heterogeneity, including the case SK-22 analyzed in a different time in a different study by microsatellite marker D3S1611. All data used for LOH analyses by MLPA and SNP markers together with calculated LOH ratios are summarized in additional files 2 and 3. There was no apparent difference of the clinico-pathological characteristics between the tumors with partial LOH (SK-14, SK-20, SK-22) and tumors without LOH (SK-21, SK-23).
###end p 39
###begin p 40
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLPA-based LOH analyses</bold>
###xml 25 26 25 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 129 130 129 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 194 195 194 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 226 227 226 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 285 286 285 286 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 317 318 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
MLPA-based LOH analyses. A: The MSH2/MLH1-MLPA analysis profile of healthy control DNA. B: germline del5-6 MLH1 (SK-22 patient). C: SK-22 tumor, homozygous del5-6 of MLH1 indicating LOH at LGR. D: SK-14 germline, MSH2 del1-7. E: SK-14 tumor, retention of heterozygosity at LGR region. F: SK-20 germline, dup5-6 MSH2. G: SK-20 tumor, retention of heterozygosity at LGR region. Arrows, deleted/duplicated exons; asterisk, LOH.
###end p 40
###begin p 41
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP sequencing-based LOH analyses</bold>
###xml 35 36 35 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 119 120 119 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 209 210 209 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 293 294 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 362 363 362 363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 443 444 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 509 516 509 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G and H</bold>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
SNP sequencing-based LOH analyses. A: Germline DNA of SK-14 at the c.1759+107A>G (Intron11, MSH2), reverse sequencing. B: SK-14 tumor DNA showing LOH at the c.1759+107A>G (Intron11, MSH2), reverse sequencing. C: Germline DNA of SK-20 at the c.1277-118G>A (Intron7, MSH2), forward orientation. D: SK-20 tumor DNA showing LOH at the c.1277-118G>A (Intron7, MSH2). E: Germline DNA of SK-22 at the c.1-93G>A (Promotor, MLH1), forward orientation. F: SK-22 tumor DNA showing LOH at the c.1-93G>A (Promotor, MLH1). G and H: An example of DNA sequencing profiles of paired germline and tumor DNA presenting no LOH at the c.1277-118G>A (Intron7, MSH2) in the tumor. Note: LOH was calculated as described in Methods.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 351 355 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 750 754 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 882 887 882 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 964 969 964 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
The index cases of 37 families included in this study were analyzed for LGRs in the MMR genes using two MLPA kits, and 7 (19%) were found to have this type of alteration. Taking into account all mutations identified so far (28 mutations in total), including the mutations found in this study, the LGRs account for 25% of clearly pathogenic changes in MMR genes from Slovakian HNPCC families. The large deletion in the MLH1 gene, a del5-6, has not been reported in other populations and, as a single mutation, represents only 6.7% (1 of 15) of all MLH1 mutations, while LGRs in the MSH2 gene account for 50% (6 of 12) of all MSH2 mutation-positive cases [30-32] (one family with inherited MSH6 mutation is unpublished). Although large duplications in MMR genes seem to occur much less frequently than deletions [18,39-43], we uncovered one duplication of exons 5 and 6 affecting the MSH2 gene in our relatively small cohort. A duplication of these two exons in the MSH2 gene has been reported [14].
###end p 43
###begin p 44
###xml 114 124 114 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1/MSH2 </italic>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1077 1082 1077 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1086 1091 1086 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
###xml 956 963 <span type="species:ncbi:9606">patient</span>
Our results provide the first evidence that, like in many other studied populations, large genomic changes in the MLH1/MSH2 genes exist in Slovakian HNPCC families. In addition, this type of mutation is frequent, particularly in the MSH2 gene, implying that the mutation screening algorithm should begin with MLPA and not with DNA sequencing, especially in cases where the protein expression pattern of the tumor shows a loss of MSH2 protein or is unknown. For cases that lack detectable MLH1 protein expression in tumors analyzed by IHC, DNA sequencing of the MLH1 gene prior MLPA screening is more appropriate. LGR correlated strongly with MSI-H status; more than 83% tumors of LGR carriers displayed MSI-H. However, also high rate of AC-I patients with MSI-L tumors may be potentially LGR carriers (in our cohort ~33%). For patients with no FFPE tissue available for MSI analysis such as the case SK-25 in our study, MLPA assay may be considered if the patient fulfills strict AC criteria. Similarly, MMR gene expression results correlated with MLPA findings, indicative of MSH2 and MLH1 mutation.
###end p 44
###begin p 45
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1113 1118 1113 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1214 1222 1214 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1 </italic>
###xml 1253 1258 1253 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1343 1351 1343 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1 </italic>
###xml 1385 1398 1385 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TACSTD1/MSH2 </italic>
###xml 1418 1420 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1421 1423 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1502 1510 1502 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TASCTD1 </italic>
###xml 1581 1585 1581 1585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1592 1597 1592 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1601 1605 1601 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 1694 1702 1694 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TASCTD1 </italic>
###xml 1760 1765 1760 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 561 567 <span type="species:ncbi:9606">people</span>
###xml 1297 1305 <span type="species:ncbi:9606">patients</span>
Similar to what has been found in other studies, there was a high proportion 5/6 (83%) of deletions encompassing exon 1 among the MSH2 rearrangements [8,11,13,41,42,44,45]. Common origin, or founder effect, cannot be excluded for deletions of exons 1-3 detected in the patients, SK-21 and SK-28, and likewise of exons 1-7 identified in the patients, SK-14 and SK-25. The examination of haplotypes and/or breakpoints may help to determine whether this is the case. Unfortunately, the risk haplotype could not be traced in the families due to the small number of people available for examination. For deletions encompassing exon 1, determination of breakpoints by long range PCR is difficult given that 5' breakpoints may be located up to 200 kb upstream of the MSH2 transcription initiation site [44]. However, according to the preliminary results of the large on-going study to test a new methodological approach for breakpoint detection involving the LGR carriers of our work, the SK-14 and SK-25 cases do seem to share common breakpoints (Dr. Benno Rothlisberger, personal communication). For three out of five MSH2 deletion cases (SK-14, SK-21, and SK-25), we demonstrated that one breakpoint should lie in the TACSTD1 gene, which is upstream of the MSH2 gene. Current findings that some HNPCC patients carry aberrations exclusively in the TACSTD1 gene leading to the generation of TACSTD1/MSH2 fusion transcripts [46,47] led to the creation of a new version of the P003 kit (B1 version), including TASCTD1 probes to enable simultaneous MLPA analysis of this gene and the major MMR genes (MLH1 and MSH2). Using the P008 kit (MSH6/PMS2) in our cohort, we detected copy number changes for the TASCTD1 gene only in conjunction with deletions of exon(s) in the MSH2 gene.
###end p 45
###begin p 46
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 831 836 831 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 867 871 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 906 911 906 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 991 996 991 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 1021 1026 1021 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1091 1096 1091 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 1249 1253 1249 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
Although based on a small number of cases, our cumulative data from LOH analyses performed by various markers (heterozygous LGR region, SNPs, and microsatellites) indicate that partial LOH can take place at the mutated MLH1 or MSH2 loci in LGR carriers. We have adapted the term 'partial LOH' from LOH studies conducted on the chromosomal level, showing for instance partial LOH confined to one arm of a chromosome [48], and have used this term to signify concurrent retention of heterozygosity of at least one marker and loss of heterozygosity of at least one other marker within the gene. At this point, it is not clear whether partial LOH also occurs in HNPCC tumors of individuals carrying other types of MMR gene mutations, for instance point mutations. A varying frequency of LOH has been described in the literature for the MLH1 and MSH2 loci in the series of MMR gene mutation carriers. LOH at the MLH1 locus has been reported in 35-85% of all tumors with a germline mutation in the MLH1 gene [49-55]. LOH at the MSH2 locus has been described in 14-50% of all tumors with a germline MSH2 mutation [49,51,54,56]. Given that partial LOH may be not detected when only a few markers are used, it is possible that the importance of LOH events at MMR genes in HNPCC tumors is still underestimated.
###end p 46
###begin p 47
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">6</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 550 555 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
Schematic representations of partial LOHs in both genes are shown in Figure 5 and 6. The precise characterization of gene conversion events through the determination of initiating and terminating points is practically difficult; thus, annotation of the converted tract usually represents the minimal and maximal converted tracts (MinCT, MaxCT) [26]. In the tumors we examined, the overall heterozygosity of SNP markers was unexpectedly low, and thus allowed us to characterize converted tracts only partially. The microsatellite markers flanking the MLH1 or MSH2 gene that were tested in previous studies from our laboratory [32,38] were also uninformative, due to the presence of instability in these MMR deficient tumors.
###end p 47
###begin p 48
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schematic representation of partial LOH in the <italic>MLH1 </italic>gene</bold>
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 203 204 203 204 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a1, a2</italic>
###xml 262 269 <span type="species:ncbi:9606">patient</span>
Schematic representation of partial LOH in the MLH1 gene. A: The structure of the MLH1 gene with 19 exons (open boxes numbered 1-19). Exon and intron (solid line) sizes are drawn approximately to scale. B: The scheme of two MLH1 alleles (a1, a2) in the tumor of patient SK-22 displaying LOH at SNP marker c.1-93G>A, homozygous del5-6 (LOH), and retention of heterozygosity at the microsatellite marker, D3S1611, located in intron 12. MinCT, minimal converted tract; MaxCT, maximal converted tract; the initiating point of putative gene conversion can lie anywhere within the blue colored box; question mark indicates that extension of MaxCT remains unknown. Note: The term 'initiating point' is not used in the sense to indicate direction of gene conversion.
###end p 48
###begin p 49
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schematic representation of partial LOHs in the <italic>MSH2 </italic>gene</bold>
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 204 205 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a1, a2</italic>
###xml 432 433 432 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 453 458 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a1, a2</italic>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 263 270 <span type="species:ncbi:9606">patient</span>
###xml 491 498 <span type="species:ncbi:9606">patient</span>
Schematic representation of partial LOHs in the MSH2 gene. A: The structure of the MSH2 gene with 16 exons (open boxes numbered 1-16). Exon and intron (solid line) sizes are drawn approximately to scale. B: The scheme of two MSH2 alleles (a1, a2) in the tumor of patient SK-14 displaying retention of heterozygosity (no LOH) at del1-7 (dotted line) and LOH at SNP markers c.1511-91G>T, c.1511-9A>T, c.1661+12G>A, and c.1759+107A>G. C: The scheme of two MSH2 alleles (a1, a2) in the tumor of patient SK-20 displaying retention of heterozygosity (no LOH) at dup5-6 (presumably tandemly arranged) and LOH at SNP markers c.211+9C>G, c.211+98C>T, both in intron 1, and c.1277-118G>A in intron 7. MinCT, minimal converted tract; MaxCT, maximal converted tract; the initiating point of putative gene conversion can lie anywhere within the blue colored box; question mark indicates that extension of MaxCT and MinCT remains unknown. Note: The term 'initiating point' is not used in the sense to indicate direction of gene conversion; LOH status in the SK-20 tumor (C panel) at the c.211+9C>G and c.211+98C>T loci has been observed previously [28].
###end p 49
###begin p 50
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 487 489 487 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 492 495 492 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21 </sub>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">6</xref>
###xml 890 894 890 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alu </italic>
###xml 932 936 932 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
The underlying mechanism for partial LOH is unclear at the moment; however, it is likely that specific motifs surrounding DNA sequences involved in gene conversion [26] play a role in partial LOH. Such motifs include alternating purine and pyrimidine or polypurine and polypyrimidine tracts, minisatellite sequences, and chi-like sequences, all of which are present in the MLH1 and MSH2 genes. The only two chi sequences (5'-GCTGGTGG-3') present within the MLH1 gene, as well as the (TA)12(T)21 tract known as BAT-21, are coincidentally located in the region that we confined to the initiating point of the putative gene-conversion event in the SK-22 tumor (blue colored box in Figure 5). The regions of the MSH2 gene that we confined to the initiating points of the gene-conversion events in the SK-14 and SK-20 tumors are rich of polypyrimidine tracts (blue colored box in Figure 6). The Alu sequences, which are abundant in both MMR genes, are also considered to play a role in gene conversion; however, their action is attributed mainly to interlocus, rather than interallelic, gene-conversion events [26].
###end p 50
###begin p 51
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1471 1475 1471 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMR </italic>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
Understanding the nature of the second, i.e. somatic, hit in the respective MMR gene may be crucial for the understanding of cancer initiation in HNPCC patients. Interestingly, only in the case of SK-22 carrying an exon 5-6 del of the MLH1 gene, has the wild-type sequence been replaced by the mutated sequence encompassing a deletion of exons 5 and 6 and resulting in a homozygous alteration in the tumor. This LOH event should clearly lead to a complete inactivation of the MLH1 gene in the tumor which is in correlation with MSI and IHC findings. In the remaining two cases of MSH2 mutation, it is difficult to distinguish which allele served as the 'donor' (unaltered) and which as the 'acceptor' (altered). Since the replaced region does not harbor a genomic rearrangement observed in the germline, the role of such a 'second hit' in tumorigenesis remains unclear. Nevertheless, in one tumor (SK-20) that could be analyzed by MSI and IHC, presumably MMR inactivation had occurred as demonstrated by the presence of high level MSI (MSI-H) and loss of MSH2 expression. It cannot be excluded that the gene conversion-mediated sequence homogenization at several SNPs plays a role in tumorigenesis. Another explanation might be the presence of a 'third hit', which is difficult to fully assess in tumor-derived DNA. Clearly, future studies on larger sets of HNPCC patients with various types of mutations are needed to confirm the occurrence of partial LOH events in the MMR genes of HNPCC tumors and to elucidate the mechanism by which they arise and their roles in tumorigenesis.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 265 275 265 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1/MSH2 </italic>
In conclusion, given that LGRs of the MSH2 gene appear to be frequent in Slovakian HNPCC families, we recommend beginning mutational screening in this population with the MSH2/MLH1-MLPA kit. We have discovered partial LOH events at mutated genes in tumors from the MLH1/MSH2 large genomic rearrangement carriers. To the best of our knowledge, this finding is novel. For the fine mapping of conversion tracts in these genes, a large set of heterozygous markers is essential. Our results also extend the limited knowledge of the role of gene conversion in cancer.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The authors declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
###xml 230 238 <span type="species:ncbi:9606">patients</span>
KZ and TS carried out the MLPA analysis. TK and MGB performed DNA sequencing and SNP analyses. KZ and MGB participated in the drafting of the manuscript. DM performed MSI analyses and DI assessed clinico-genetical features of the patients enrolled in the study. ZB conceived of the study, and participated in its design and coordination, as well as in the writing of the manuscript. All authors read and approved the final manuscript version.
###end p 57
###begin title 58
Pre-publication history
###end title 58
###begin p 59
The pre-publication history for this paper can be accessed here:
###end p 59
###begin p 60

###end p 60
###begin title 61
Supplementary Material
###end title 61
###begin title 62
Additional file 1
###end title 62
###begin p 63
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOH analysis by the microsatellite marker D3S1611 in SK-22 patient</bold>
###xml 59 66 <span type="species:ncbi:9606">patient</span>
###xml 188 195 <span type="species:ncbi:9606">patient</span>
LOH analysis by the microsatellite marker D3S1611 in SK-22 patient. An example of tumor with LOH at the D3S1611 marker, Retention of heterozygosity at the D3S1611 marker in tumor of SK-22 patient.
###end p 63
###begin p 64
Click here for file
###end p 64
###begin title 65
Additional file 2
###end title 65
###begin p 66
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Data from LOH analyses by MLPA</bold>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
Data from LOH analyses by MLPA. Table of the average dosage quotients of exons affected by LGR in matched normal and tumor DNA of patients with identified LGRs in the MLH1 or MSH2 genes and calculated LOH ratios.
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Additional file 3
###end title 68
###begin p 69
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Data from LOH analyses by MLPA</bold>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Data from LOH analyses by MLPA. Table of the signal intensities of SNP alleles in matched normal and tumor DNA in the patients with identified LGRs in the MLH1 or MSH2 genes and calculated LOH ratios.
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
We thank Dr. Giancarlo Marra and Dr. Pavel Babal for immunohistochemical data. This study was financially supported by the Ministry of Health of Slovak Republic (2006/26-NOU-02) and the VEGA Grant Agency (2/5131/25, 2/0039/08).
###end p 72
###begin article-title 73
Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers
###end article-title 73
###begin article-title 74
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)
###end article-title 74
###begin article-title 75
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC
###end article-title 75
###begin article-title 76
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines
###end article-title 76
###begin article-title 77
New aspects in molecular diagnosis of Lynch syndrome (HNPCC)
###end article-title 77
###begin article-title 78
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer
###end article-title 78
###begin article-title 79
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance
###end article-title 79
###begin article-title 80
MSH2 genomic deletions are a frequent cause of HNPCC
###end article-title 80
###begin article-title 81
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach
###end article-title 81
###begin article-title 82
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene
###end article-title 82
###begin article-title 83
Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes
###end article-title 83
###begin article-title 84
Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families
###end article-title 84
###begin article-title 85
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification
###end article-title 85
###begin article-title 86
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients
###end article-title 86
###begin article-title 87
Large genomic rearrangements and germline epimutations in Lynch syndrome
###end article-title 87
###begin article-title 88
Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study)
###end article-title 88
###begin article-title 89
Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC)
###end article-title 89
###begin article-title 90
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Genomic rearrangements in MSH2 and MLH1 are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer
###end article-title 90
###begin article-title 91
High proportion of large genomic rearrangements in hMSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families of the Basque Country
###end article-title 91
###begin article-title 92
Founding mutations and Alu-mediated recombination in hereditary colon cancer
###end article-title 92
###begin article-title 93
A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population
###end article-title 93
###begin article-title 94
Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC
###end article-title 94
###begin article-title 95
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Identification of novel germline hMLH1 mutations including a 22 kb Alu-mediated deletion in patients with familial colorectal cancer
###end article-title 95
###begin article-title 96
Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments
###end article-title 96
###begin article-title 97
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations
###end article-title 97
###begin article-title 98
###xml 43 48 <span type="species:ncbi:9606">human</span>
Gene conversion: mechanisms, evolution and human disease
###end article-title 98
###begin article-title 99
Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach
###end article-title 99
###begin article-title 100
Multiplex SNaPshot genotyping for detecting loss of heterozygosity in the mismatch-repair genes MLH1 and MSH2 in microsatellite-unstable tumors
###end article-title 100
###begin article-title 101
Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas
###end article-title 101
###begin article-title 102
Novel MLH1 and MSH2 germline mutations in the first HNPCC families identified in Slovakia
###end article-title 102
###begin article-title 103
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Novel and recurrent germline alterations in the MLH1 and MSH2 genes identified in hereditary nonpolyposis colorectal cancer patients in Slovakia
###end article-title 103
###begin article-title 104
The role of clinical criteria, genetic and epigenetic alterations in Lynch-syndrome diagnosis
###end article-title 104
###begin article-title 105
Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer
###end article-title 105
###begin article-title 106
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
###end article-title 106
###begin article-title 107
Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue
###end article-title 107
###begin article-title 108
No evidence for dual role of loss of heterozygosity in hereditary non-polyposis colorectal cancer
###end article-title 108
###begin article-title 109
Extensive molecular screening for hereditary non-polyposis colorectal cancer
###end article-title 109
###begin article-title 110
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients
###end article-title 110
###begin article-title 111
Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements
###end article-title 111
###begin article-title 112
Large genomic aberrations in MSH2 and MLH1 genes are frequent in Chinese colorectal cancer
###end article-title 112
###begin article-title 113
Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC
###end article-title 113
###begin article-title 114
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer
###end article-title 114
###begin article-title 115
Partial duplications of the MSH2 and MLH1 genes in hereditary nonpolyposis colorectal cancer
###end article-title 115
###begin article-title 116
The 5' region of the MSH2 gene involved in hereditary non-polyposis colorectal cancer contains a high density of recombinogenic sequences
###end article-title 116
###begin article-title 117
Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA
###end article-title 117
###begin article-title 118
Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome
###end article-title 118
###begin article-title 119
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1
###end article-title 119
###begin article-title 120
###xml 51 56 <span type="species:ncbi:9606">human</span>
Evidence for two bladder cancer suppressor loci on human chromosome 9
###end article-title 120
###begin article-title 121
Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers
###end article-title 121
###begin article-title 122
Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer
###end article-title 122
###begin article-title 123
Loss or somatic mutations of hMSH2 occur in hereditary nonpolyposis colorectal cancers with hMSH2 germline mutations
###end article-title 123
###begin article-title 124
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Tumorigenesis in colorectal tumors from patients with hereditary non-polyposis colorectal cancer
###end article-title 124
###begin article-title 125
Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers
###end article-title 125
###begin article-title 126
Causes of microsatellite instability in colorectal tumors: implications for hereditary non-polyposis colorectal cancer screening
###end article-title 126
###begin article-title 127
Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer?
###end article-title 127
###begin article-title 128
Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer
###end article-title 128

